insulin
Insulin is essential diabetes medicine. Its F tier here concerns bodybuilding use, where controlled muscle-gain evidence is missing and severe low blood sugar is a documented risk.
Peptide hormone and diabetes medicine
- Human insulin and analogs differ
- Product-specific concentration and duration
- Diabetes treatment is separate from the stack grade
Why is a lifesaving medicine in F tier here?
Insulin is essential treatment for type 1 diabetes and is also used in type 2 diabetes. Its F grade applies to nonmedical muscle-building use, not its value as diabetes treatment.
NIDDK · why type 1 diabetes needs insulin
Patient guidance
NIDDK · why type 1 diabetes needs insulin
Type 1 diabetes requires insulin replacement. Too little insulin can cause diabetic ketoacidosis, a medical emergency.
Read the original sourceHumulin R · benefit and safety
US product label
Humulin R U-100 (insulin human) injection label, Eli Lilly. DailyMed SPL set id b519bd83-038c-4ec5-a231-a51ec5cc291f.
Regular human insulin treats diabetes. The label identifies hypoglycemia, potassium depletion, allergic reactions, weight gain, edema and injection-site changes.
A diabetes indication does not establish benefit for bodybuilding.
Read the original sourceHealthy-person muscle gain · no controlled trial
PubMed and ClinicalTrials.gov records
PubMed and ClinicalTrials.gov records for exogenous insulin and healthy-person muscle gain.
The cited PubMed records include one hypoglycemia case, and the registry records cover five other conditions. They include no controlled healthy-person insulin trial measuring bodybuilding hypertrophy.
- The cited records distinguish muscle physiology studies from controlled healthy-person bodybuilding outcomes.
Human insulin is a peptide hormone. Pharmaceutical regular human insulin is made with recombinant DNA technology; insulin analogs have altered structures and different time-action profiles.
What is the main risk?
Too much insulin can cause severe hypoglycemia, meaning dangerously low blood sugar. It can lead to seizures, coma or death.
The 2019 emergency report describes a bodybuilder who arrived in a coma and needed repeated glucose infusions. Eating something sweet does not guarantee that a serious episode is over.
Emergency case · severe hypoglycemia
Case report
The Journal of emergency medicine, 2019. PMID 30527564.
A 30-year-old bodybuilder presented in a coma and needed repeated glucose infusions. The cause was concealed insulin use.
- Participants / model
- One person
This documents a serious event. It does not estimate how often it occurs among users.
Read the original sourceCan it cause other side effects?
Other reported effects include weight gain, swelling, injection-site changes and allergic reactions. Low potassium can cause dangerous heart-rhythm problems. Frequency depends on the product and treatment setting.
Humulin R · benefit and safety
US product label
Humulin R U-100 (insulin human) injection label, Eli Lilly. DailyMed SPL set id b519bd83-038c-4ec5-a231-a51ec5cc291f.
Regular human insulin treats diabetes. The label identifies hypoglycemia, potassium depletion, allergic reactions, weight gain, edema and injection-site changes.
A diabetes indication does not establish benefit for bodybuilding.
Read the original sourceDoes injecting insulin help healthy people gain muscle?
The cited evidence does not establish a long-term muscle or strength benefit. Short laboratory experiments and reports from people taking several hormones do not establish that outcome.
Healthy-person muscle gain · no controlled trial
PubMed and ClinicalTrials.gov records
PubMed and ClinicalTrials.gov records for exogenous insulin and healthy-person muscle gain.
The cited PubMed records include one hypoglycemia case, and the registry records cover five other conditions. They include no controlled healthy-person insulin trial measuring bodybuilding hypertrophy.
- The cited records distinguish muscle physiology studies from controlled healthy-person bodybuilding outcomes.
What about bigger bodybuilders who report using it?
The 2024 study measured body size and blood markers at one point in time. Insulin use overlapped with steroids and growth hormone, and hormone exposure came from questionnaires. That design cannot tell us how much muscle insulin caused.
Bodybuilder survey · confounded blood markers
Cross-sectional observational study
Sports medicine - open, 2024. PMID 38536564.
In 92 male bodybuilders and 45 controls, hormone use was associated with altered liver and lipid markers. Insulin use overlapped with anabolic steroids and growth hormone.
- Participants / model
- 92 male recreational bodybuilders and 45 controls
Hormone exposure was self-reported. Neither larger body size nor abnormal bloodwork can be attributed to insulin alone.
Read the original sourceDoes being anabolic mean more insulin builds more muscle?
Insulin can improve protein balance by slowing breakdown. That is not the same measurement as making new muscle, and increasing insulin does not necessarily increase protein synthesis.
In the seven-person forearm experiment, net protein balance improved mainly because breakdown fell. In Greenhaff’s experiment, extra insulin did not increase muscle protein synthesis when amino-acid availability was held constant.
Seven-person forearm study · protein turnover
Human physiology study
The Journal of clinical investigation, 1987. PMID 3298320.
During a two-hour experiment in seven healthy men, insulin improved net protein balance mainly by reducing breakdown. Protein incorporation did not increase.
- Participants / model
- Seven healthy men
- Follow-up
- Two hours
A local physiology experiment did not measure training gains or long-term muscle growth.
Read the original sourceAmino-acid clamp · more insulin did not add synthesis
Human physiology study
American journal of physiology. Endocrinology and metabolism, 2008. PMID 18577697.
With amino-acid availability held constant, raising insulin reduced leg protein breakdown, but further increases did not add suppression or increase muscle protein synthesis.
- Participants / model
- Healthy young men
The measured ceiling applies to this experiment. It is not a blood-level target or a bodybuilding regimen.
Read the original sourceDo all physiology studies find exactly the same thing?
Responses differ by age, adiposity, nutrient supply and whether researchers measure muscle or whole-body turnover. The 16-person aging study found a weaker breakdown response in older participants. Other clamps reported changes in synthesis, including one combining insulin with amino acids.
Young versus older adults · breakdown response
Human physiology study
The American journal of clinical nutrition, 2009. PMID 19740975.
Insulin reduced leg protein breakdown by 47% in eight younger participants versus a nonsignificant 12% in eight older participants. Muscle protein synthesis did not differ.
- Participants / model
- Eight younger and eight older adults
- Follow-up
- 1.5-hour clamp
Age and experimental conditions affect the response; this was not a muscle-gain trial.
Read the original sourceWhole-body clamp · context changes the response
Human physiology study
The journals of gerontology. Series A, Biological sciences and medical sciences, 2006. PMID 16510859.
Protein synthesis rose less in older than younger participants while breakdown decreased in both groups. Adiposity helped explain the weaker anabolic response.
- Participants / model
- 42 adults: 23 younger and 19 older
Whole-body protein metabolism is not identical to muscle protein synthesis or a training outcome.
Read the original sourceOlder men · insulin plus amino acids
Human physiology study
Diabetes, 2015. PMID 26015550.
Combined insulin and amino-acid delivery raised muscle protein synthesis only in the healthy-weight group. Obese participants showed a different balance of synthesis and breakdown.
- Participants / model
- 26 men aged 55–75: 11 obese and 15 healthy-weight
The combined intervention cannot isolate the effect of insulin, and baseline leg lean mass and strength did not differ.
Read the original sourceFor glucose control, insulin increases uptake by muscle and fat and reduces glucose release from the liver.
Novolin R · mechanism and interactions
US product label
Novolin R (insulin human) injection label, Novo Nordisk. DailyMed SPL set id aee7f1f3-612c-4027-8ce9-4fd1f41eed71.
Insulin lowers blood glucose by increasing uptake and reducing liver output. The label explains drug interactions and why activity, meals and organ function affect requirements.
Read the original sourceWhat does a controlled diabetes trial show?
ONWARDS 1 compared weekly insulin icodec with daily glargine in adults with type 2 diabetes. Both improved glucose control; icodec produced a slightly larger HbA1c reduction.
| Outcome | Weekly icodec | Daily glargine |
|---|---|---|
| HbA1c reduction at week 52 | 1.55 percentage points | 1.35 percentage points |
| Time in range during weeks 48–52 | 71.9% | 66.9% |
| Significant or severe hypoglycemia through week 83 | 0.30 events per person-year | 0.16 events per person-year |
These are trial estimates in diabetes. Event rates are not percentages of participants.
ONWARDS 1 · weekly versus daily insulin
Randomized phase 3a trial
The New England journal of medicine, 2023. PMID 37356066.
Icodec reduced HbA1c slightly more than glargine. Clinically significant or severe hypoglycemia occurred more often with icodec over the extended follow-up.
- Participants / model
- 984 adults with type 2 diabetes who had not previously used insulin
- Follow-up
- 52-week primary endpoint; follow-up through week 83
- Study design
- Open-label, treat-to-target comparison, 492 per group
- Funding
- Novo Nordisk
The trial studied diabetes management, not healthy-person weight or muscle gain.
Read the original sourceCan early insulin treatment lead to remission in type 2 diabetes?
A randomized trial at nine Chinese centers found more one-year remission after short-term intensive insulin treatment than after oral glucose-lowering drugs.
The trial enrolled 382 newly diagnosed adults. Treatment stopped after normal glucose had been maintained for two weeks, followed by diet and exercise follow-up. This was a monitored clinical strategy.
| Initial treatment | Remission |
|---|---|
| Insulin pump | 51.1% |
| Multiple daily insulin injections | 44.9% |
| Oral agents | 26.7% |
These results apply to newly diagnosed type 2 diabetes. They do not show a permanent cure or support stopping essential insulin in type 1 diabetes.
China trial · early type 2 diabetes remission
Randomized clinical trial
Lancet (London, England), 2008. PMID 18502299.
At one year, reported remission was 51.1% after pump insulin, 44.9% after multiple daily injections and 26.7% after oral agents.
- Participants / model
- 382 newly diagnosed adults aged 25–70 at nine Chinese centers
- Follow-up
- One year after initial treatment
- Study design
- Parallel-group trial; per-protocol analysis
English-language report of a China-conducted trial. Remission after monitored treatment is not a permanent cure or permission to stop insulin in type 1 diabetes.
Read the original sourceAre regular, inhaled and weekly insulin interchangeable?
Regular, inhaled, and weekly insulin products differ in molecule, concentration, delivery device, and duration. Each must match the prescription.
| Product | Form | Main distinction |
|---|---|---|
| Humulin R / Novolin R | Regular human insulin injection | Short-acting; intravenous use requires medical supervision. |
| Humulin R U-500 | Concentrated regular human insulin injection | Different concentration and longer time-action profile. |
| Afrezza | Inhaled human insulin | Age 6 and older; lung screening required; basal insulin still needed in type 1 diabetes. |
| Awiqli | Weekly insulin icodec injection | Long-acting analog for adults with type 2 diabetes. |
Humulin R · benefit and safety
US product label
Humulin R U-100 (insulin human) injection label, Eli Lilly. DailyMed SPL set id b519bd83-038c-4ec5-a231-a51ec5cc291f.
Regular human insulin treats diabetes. The label identifies hypoglycemia, potassium depletion, allergic reactions, weight gain, edema and injection-site changes.
A diabetes indication does not establish benefit for bodybuilding.
Read the original sourceHumulin R U-500 · concentration and duration
US product label
Humulin R U-500 (insulin human) injection label, Eli Lilly. DailyMed SPL set id b60e8dd0-1d48-4dc9-87fd-e14675255e8c.
U-500 is five times as concentrated as U-100. Dosing errors have caused severe harm; the vial and pen require their specified delivery devices.
The concentration also changes the time-action profile. Never infer that matching volume means matching units.
Read the original sourceAfrezza · inhaled insulin
US product label
Afrezza (insulin human) inhalation powder label, MannKind. DailyMed SPL set id 29f4637b-e204-425b-b89c-7238008d8c10.
The current US label covers diabetes from age 6. Asthma and COPD are contraindications because of acute bronchospasm; spirometry is required. Type 1 diabetes also requires basal insulin.
Approval of an inhaled product does not make an injected insulin inhalable. The boxed warning is product-specific.
Read the original sourceAwiqli · once-weekly basal insulin
US product label
Awiqli (insulin icodec-abae) label, Novo Nordisk. DailyMed SPL set id 5162b93e-5775-4581-a5e9-e8783ae0acd7.
The March 2026 US label covers once-weekly insulin icodec for adults with type 2 diabetes. It has product-specific switching and missed-dose instructions.
It is an insulin analog, not weekly regular human insulin. The US indication does not cover type 1 diabetes.
Read the original sourceDoes every insulin have the same boxed warning?
Afrezza’s boxed warning concerns acute bronchospasm in people with chronic lung disease. Its absence from an injected regular-insulin label does not remove the hypoglycemia hazard.
Afrezza · inhaled insulin
US product label
Afrezza (insulin human) inhalation powder label, MannKind. DailyMed SPL set id 29f4637b-e204-425b-b89c-7238008d8c10.
The current US label covers diabetes from age 6. Asthma and COPD are contraindications because of acute bronchospasm; spirometry is required. Type 1 diabetes also requires basal insulin.
Approval of an inhaled product does not make an injected insulin inhalable. The boxed warning is product-specific.
Read the original sourceHumulin R · benefit and safety
US product label
Humulin R U-100 (insulin human) injection label, Eli Lilly. DailyMed SPL set id b519bd83-038c-4ec5-a231-a51ec5cc291f.
Regular human insulin treats diabetes. The label identifies hypoglycemia, potassium depletion, allergic reactions, weight gain, edema and injection-site changes.
A diabetes indication does not establish benefit for bodybuilding.
Read the original sourceWhy does the concentration matter?
U-100 contains 100 units per milliliter; U-500 contains 500. Confusing units with volume or using the wrong device can cause a major dosing error.
Humulin R U-500 · concentration and duration
US product label
Humulin R U-500 (insulin human) injection label, Eli Lilly. DailyMed SPL set id b60e8dd0-1d48-4dc9-87fd-e14675255e8c.
U-500 is five times as concentrated as U-100. Dosing errors have caused severe harm; the vial and pen require their specified delivery devices.
The concentration also changes the time-action profile. Never infer that matching volume means matching units.
Read the original sourceHas U-500 actually been studied in randomized trials?
A 2015 trial randomized 325 adults with severely insulin-resistant type 2 diabetes to two U-500 treatment schedules. It did not study bodybuilding.
U-500 randomized trial · 325 adults
Randomized clinical trial
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2015. PMID 25813411.
A 2015 trial randomized 325 adults with type 2 diabetes to two U-500 schedules and compared HbA1c over 24 weeks.
- Participants / model
- 325 adults with inadequately controlled type 2 diabetes and high insulin requirements
- Follow-up
- 24 weeks
- Study design
- Open-label, parallel-group, active comparison
A 2016 correction exists, but it does not provide detailed corrected regimen estimates.
Read the original sourceDoes insulin have one half-life or duration?
Duration depends on the formulation and route. A short plasma half-life does not mean an injection's glucose-lowering effect has ended.
The Novolin R label describes roughly eight hours of effect after subcutaneous administration, with substantial variation. Awiqli is designed for weekly administration. Neither timescale can be transferred to another insulin product.
Novolin R · mechanism and interactions
US product label
Novolin R (insulin human) injection label, Novo Nordisk. DailyMed SPL set id aee7f1f3-612c-4027-8ce9-4fd1f41eed71.
Insulin lowers blood glucose by increasing uptake and reducing liver output. The label explains drug interactions and why activity, meals and organ function affect requirements.
Read the original sourceAwiqli · once-weekly basal insulin
US product label
Awiqli (insulin icodec-abae) label, Novo Nordisk. DailyMed SPL set id 5162b93e-5775-4581-a5e9-e8783ae0acd7.
The March 2026 US label covers once-weekly insulin icodec for adults with type 2 diabetes. It has product-specific switching and missed-dose instructions.
It is an insulin analog, not weekly regular human insulin. The US indication does not cover type 1 diabetes.
Read the original sourceU-500’s label reports a mean 21-hour effect in a 24-person clamp experiment, with a 13–24-hour range. Individual glucose-lowering effects can differ from that study range.
Humulin R U-500 · concentration and duration
US product label
Humulin R U-500 (insulin human) injection label, Eli Lilly. DailyMed SPL set id b60e8dd0-1d48-4dc9-87fd-e14675255e8c.
U-500 is five times as concentrated as U-100. Dosing errors have caused severe harm; the vial and pen require their specified delivery devices.
The concentration also changes the time-action profile. Never infer that matching volume means matching units.
Read the original sourceWhat can change insulin requirements or hide a low?
Other glucose-lowering drugs can increase hypoglycemia risk. Corticosteroids and growth hormone can oppose glucose lowering. Beta-blockers can make warning symptoms less obvious.
Novolin R · mechanism and interactions
US product label
Novolin R (insulin human) injection label, Novo Nordisk. DailyMed SPL set id aee7f1f3-612c-4027-8ce9-4fd1f41eed71.
Insulin lowers blood glucose by increasing uptake and reducing liver output. The label explains drug interactions and why activity, meals and organ function affect requirements.
Read the original sourceMeals, fasting, alcohol and exercise also matter. Exercise can lower glucose after the activity has finished, and alcohol can interfere with recognizing and correcting a low.
NIDDK · recognizing and treating low glucose
Patient guidance
NIDDK · recognizing and treating low glucose
Low glucose can cause sweating, shaking, hunger, confusion and loss of consciousness. Severe episodes require immediate treatment and may require glucagon and emergency help.
Read the original sourceWhat about kidney disease, pregnancy or breastfeeding?
Kidney or liver impairment can increase hypoglycemia risk. Insulin requirements can change during pregnancy and breastfeeding, so the product and monitoring plan need review. Human insulin has extensive pregnancy experience; poorly controlled diabetes itself carries risks.
Novolin R · mechanism and interactions
US product label
Novolin R (insulin human) injection label, Novo Nordisk. DailyMed SPL set id aee7f1f3-612c-4027-8ce9-4fd1f41eed71.
Insulin lowers blood glucose by increasing uptake and reducing liver output. The label explains drug interactions and why activity, meals and organ function affect requirements.
Read the original sourceCan repeated injections cause lumps or affect absorption?
Repeated use at the same sites can produce thickened fatty tissue and alter absorption. A 500-patient study found frequent lipohypertrophy, including changes missed by clinical examination.
Injection-site study · lumps and absorption
Cross-sectional observational study
Primary care diabetes, 2021. PMID 34154931.
Among 500 insulin-treated patients, 44.6% had clinically detected lipohypertrophy and ultrasound found another 13.4%. Poor site rotation and needle reuse were associated with it.
- Participants / model
- 500 patients in India using injected insulin for at least two years
This single-center diabetes sample does not establish the rate in all insulin users or bodybuilders.
Read the original sourceThe labels advise rotating sites and avoiding affected areas. A switch from repeatedly injecting into abnormal tissue to normal tissue can change absorption and cause hypoglycemia, so glucose monitoring matters.
Humulin R · benefit and safety
US product label
Humulin R U-100 (insulin human) injection label, Eli Lilly. DailyMed SPL set id b519bd83-038c-4ec5-a231-a51ec5cc291f.
Regular human insulin treats diabetes. The label identifies hypoglycemia, potassium depletion, allergic reactions, weight gain, edema and injection-site changes.
A diabetes indication does not establish benefit for bodybuilding.
Read the original sourceCan I stop insulin when my glucose looks normal?
Normal readings can mean the insulin is working. In type 1 diabetes, stopping replacement can cause ketoacidosis. Changes in type 2 diabetes depend on the diagnosis and treatment response.
NIDDK · why type 1 diabetes needs insulin
Patient guidance
NIDDK · why type 1 diabetes needs insulin
Type 1 diabetes requires insulin replacement. Too little insulin can cause diabetic ketoacidosis, a medical emergency.
Read the original sourceChina trial · early type 2 diabetes remission
Randomized clinical trial
Lancet (London, England), 2008. PMID 18502299.
At one year, reported remission was 51.1% after pump insulin, 44.9% after multiple daily injections and 26.7% after oral agents.
- Participants / model
- 382 newly diagnosed adults aged 25–70 at nine Chinese centers
- Follow-up
- One year after initial treatment
- Study design
- Parallel-group trial; per-protocol analysis
English-language report of a China-conducted trial. Remission after monitored treatment is not a permanent cure or permission to stop insulin in type 1 diabetes.
Read the original sourceMissed-dose instructions differ by product. A weekly analog and a mealtime insulin are not handled with the same catch-up rule; use the instructions for the prescribed product and the diabetes care plan.
Awiqli · once-weekly basal insulin
US product label
Awiqli (insulin icodec-abae) label, Novo Nordisk. DailyMed SPL set id 5162b93e-5775-4581-a5e9-e8783ae0acd7.
The March 2026 US label covers once-weekly insulin icodec for adults with type 2 diabetes. It has product-specific switching and missed-dose instructions.
It is an insulin analog, not weekly regular human insulin. The US indication does not cover type 1 diabetes.
Read the original sourceNovolin R · mechanism and interactions
US product label
Novolin R (insulin human) injection label, Novo Nordisk. DailyMed SPL set id aee7f1f3-612c-4027-8ce9-4fd1f41eed71.
Insulin lowers blood glucose by increasing uptake and reducing liver output. The label explains drug interactions and why activity, meals and organ function affect requirements.
Read the original sourceIs insulin allowed in tested sport, or validated as part of a growth-hormone stack?
WADA prohibits insulins and insulin mimetics at all times under S4.4.2. The cited evidence does not establish a safe, effective insulin-and-growth-hormone bodybuilding regimen.
WADA 2026 · insulin in sport
Anti-doping rules
WADA 2026 · insulin in sport
Insulins and insulin mimetics are prohibited at all times under S4.4.2. Athletes requiring treatment must follow the applicable therapeutic-use exemption process.
Read the original sourceHealthy-person muscle gain · no controlled trial
PubMed and ClinicalTrials.gov records
PubMed and ClinicalTrials.gov records for exogenous insulin and healthy-person muscle gain.
The cited PubMed records include one hypoglycemia case, and the registry records cover five other conditions. They include no controlled healthy-person insulin trial measuring bodybuilding hypertrophy.
- The cited records distinguish muscle physiology studies from controlled healthy-person bodybuilding outcomes.
Growth hormone can oppose insulin's glucose-lowering effect, but it cannot predictably reverse an insulin overdose. No clinical study establishes a safe insulin-and-growth-hormone bodybuilding regimen.
Novolin R · mechanism and interactions
US product label
Novolin R (insulin human) injection label, Novo Nordisk. DailyMed SPL set id aee7f1f3-612c-4027-8ce9-4fd1f41eed71.
Insulin lowers blood glucose by increasing uptake and reducing liver output. The label explains drug interactions and why activity, meals and organ function affect requirements.
Read the original sourceStudies and sources
Humulin R · benefit and safety
US product label
Humulin R U-100 (insulin human) injection label, Eli Lilly. DailyMed SPL set id b519bd83-038c-4ec5-a231-a51ec5cc291f.
Regular human insulin treats diabetes. The label identifies hypoglycemia, potassium depletion, allergic reactions, weight gain, edema and injection-site changes.
A diabetes indication does not establish benefit for bodybuilding.
Read the original sourceNovolin R · mechanism and interactions
US product label
Novolin R (insulin human) injection label, Novo Nordisk. DailyMed SPL set id aee7f1f3-612c-4027-8ce9-4fd1f41eed71.
Insulin lowers blood glucose by increasing uptake and reducing liver output. The label explains drug interactions and why activity, meals and organ function affect requirements.
Read the original sourceHumulin R U-500 · concentration and duration
US product label
Humulin R U-500 (insulin human) injection label, Eli Lilly. DailyMed SPL set id b60e8dd0-1d48-4dc9-87fd-e14675255e8c.
U-500 is five times as concentrated as U-100. Dosing errors have caused severe harm; the vial and pen require their specified delivery devices.
The concentration also changes the time-action profile. Never infer that matching volume means matching units.
Read the original sourceAfrezza · inhaled insulin
US product label
Afrezza (insulin human) inhalation powder label, MannKind. DailyMed SPL set id 29f4637b-e204-425b-b89c-7238008d8c10.
The current US label covers diabetes from age 6. Asthma and COPD are contraindications because of acute bronchospasm; spirometry is required. Type 1 diabetes also requires basal insulin.
Approval of an inhaled product does not make an injected insulin inhalable. The boxed warning is product-specific.
Read the original sourceAwiqli · once-weekly basal insulin
US product label
Awiqli (insulin icodec-abae) label, Novo Nordisk. DailyMed SPL set id 5162b93e-5775-4581-a5e9-e8783ae0acd7.
The March 2026 US label covers once-weekly insulin icodec for adults with type 2 diabetes. It has product-specific switching and missed-dose instructions.
It is an insulin analog, not weekly regular human insulin. The US indication does not cover type 1 diabetes.
Read the original sourceSeven-person forearm study · protein turnover
Human physiology study
The Journal of clinical investigation, 1987. PMID 3298320.
During a two-hour experiment in seven healthy men, insulin improved net protein balance mainly by reducing breakdown. Protein incorporation did not increase.
- Participants / model
- Seven healthy men
- Follow-up
- Two hours
A local physiology experiment did not measure training gains or long-term muscle growth.
Read the original sourceAmino-acid clamp · more insulin did not add synthesis
Human physiology study
American journal of physiology. Endocrinology and metabolism, 2008. PMID 18577697.
With amino-acid availability held constant, raising insulin reduced leg protein breakdown, but further increases did not add suppression or increase muscle protein synthesis.
- Participants / model
- Healthy young men
The measured ceiling applies to this experiment. It is not a blood-level target or a bodybuilding regimen.
Read the original sourceYoung versus older adults · breakdown response
Human physiology study
The American journal of clinical nutrition, 2009. PMID 19740975.
Insulin reduced leg protein breakdown by 47% in eight younger participants versus a nonsignificant 12% in eight older participants. Muscle protein synthesis did not differ.
- Participants / model
- Eight younger and eight older adults
- Follow-up
- 1.5-hour clamp
Age and experimental conditions affect the response; this was not a muscle-gain trial.
Read the original sourceWhole-body clamp · context changes the response
Human physiology study
The journals of gerontology. Series A, Biological sciences and medical sciences, 2006. PMID 16510859.
Protein synthesis rose less in older than younger participants while breakdown decreased in both groups. Adiposity helped explain the weaker anabolic response.
- Participants / model
- 42 adults: 23 younger and 19 older
Whole-body protein metabolism is not identical to muscle protein synthesis or a training outcome.
Read the original sourceOlder men · insulin plus amino acids
Human physiology study
Diabetes, 2015. PMID 26015550.
Combined insulin and amino-acid delivery raised muscle protein synthesis only in the healthy-weight group. Obese participants showed a different balance of synthesis and breakdown.
- Participants / model
- 26 men aged 55–75: 11 obese and 15 healthy-weight
The combined intervention cannot isolate the effect of insulin, and baseline leg lean mass and strength did not differ.
Read the original sourceBodybuilder survey · confounded blood markers
Cross-sectional observational study
Sports medicine - open, 2024. PMID 38536564.
In 92 male bodybuilders and 45 controls, hormone use was associated with altered liver and lipid markers. Insulin use overlapped with anabolic steroids and growth hormone.
- Participants / model
- 92 male recreational bodybuilders and 45 controls
Hormone exposure was self-reported. Neither larger body size nor abnormal bloodwork can be attributed to insulin alone.
Read the original sourceEmergency case · severe hypoglycemia
Case report
The Journal of emergency medicine, 2019. PMID 30527564.
A 30-year-old bodybuilder presented in a coma and needed repeated glucose infusions. The cause was concealed insulin use.
- Participants / model
- One person
This documents a serious event. It does not estimate how often it occurs among users.
Read the original sourceInjection-site study · lumps and absorption
Cross-sectional observational study
Primary care diabetes, 2021. PMID 34154931.
Among 500 insulin-treated patients, 44.6% had clinically detected lipohypertrophy and ultrasound found another 13.4%. Poor site rotation and needle reuse were associated with it.
- Participants / model
- 500 patients in India using injected insulin for at least two years
This single-center diabetes sample does not establish the rate in all insulin users or bodybuilders.
Read the original sourceONWARDS 1 · weekly versus daily insulin
Randomized phase 3a trial
The New England journal of medicine, 2023. PMID 37356066.
Icodec reduced HbA1c slightly more than glargine. Clinically significant or severe hypoglycemia occurred more often with icodec over the extended follow-up.
- Participants / model
- 984 adults with type 2 diabetes who had not previously used insulin
- Follow-up
- 52-week primary endpoint; follow-up through week 83
- Study design
- Open-label, treat-to-target comparison, 492 per group
- Funding
- Novo Nordisk
The trial studied diabetes management, not healthy-person weight or muscle gain.
Read the original sourceChina trial · early type 2 diabetes remission
Randomized clinical trial
Lancet (London, England), 2008. PMID 18502299.
At one year, reported remission was 51.1% after pump insulin, 44.9% after multiple daily injections and 26.7% after oral agents.
- Participants / model
- 382 newly diagnosed adults aged 25–70 at nine Chinese centers
- Follow-up
- One year after initial treatment
- Study design
- Parallel-group trial; per-protocol analysis
English-language report of a China-conducted trial. Remission after monitored treatment is not a permanent cure or permission to stop insulin in type 1 diabetes.
Read the original sourceU-500 randomized trial · 325 adults
Randomized clinical trial
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2015. PMID 25813411.
A 2015 trial randomized 325 adults with type 2 diabetes to two U-500 schedules and compared HbA1c over 24 weeks.
- Participants / model
- 325 adults with inadequately controlled type 2 diabetes and high insulin requirements
- Follow-up
- 24 weeks
- Study design
- Open-label, parallel-group, active comparison
A 2016 correction exists, but it does not provide detailed corrected regimen estimates.
Read the original sourceNIDDK · recognizing and treating low glucose
Patient guidance
NIDDK · recognizing and treating low glucose
Low glucose can cause sweating, shaking, hunger, confusion and loss of consciousness. Severe episodes require immediate treatment and may require glucagon and emergency help.
Read the original sourceNIDDK · why type 1 diabetes needs insulin
Patient guidance
NIDDK · why type 1 diabetes needs insulin
Type 1 diabetes requires insulin replacement. Too little insulin can cause diabetic ketoacidosis, a medical emergency.
Read the original sourceWADA 2026 · insulin in sport
Anti-doping rules
WADA 2026 · insulin in sport
Insulins and insulin mimetics are prohibited at all times under S4.4.2. Athletes requiring treatment must follow the applicable therapeutic-use exemption process.
Read the original sourceHealthy-person muscle gain · no controlled trial
PubMed and ClinicalTrials.gov records
PubMed and ClinicalTrials.gov records for exogenous insulin and healthy-person muscle gain.
The cited PubMed records include one hypoglycemia case, and the registry records cover five other conditions. They include no controlled healthy-person insulin trial measuring bodybuilding hypertrophy.
- The cited records distinguish muscle physiology studies from controlled healthy-person bodybuilding outcomes.
NHS · emergency care
Patient guidance
NHS. Low blood sugar (hypoglycaemia). Last reviewed 3 August 2023.
For an unconscious person with severe low glucose, the NHS says to give no food or drink by mouth because swallowing is unsafe. It describes the recovery position, glucagon if available and the responder knows how to use it, and emergency help.
This guidance supports emergency first aid, not a bodybuilding insulin regimen. Emergency telephone numbers differ by country.
Read the original sourceWhy is insulin in F tier?
The F tier applies only to nonmedical muscle building, where controlled benefit evidence is absent and severe hypoglycemia is well documented. Insulin remains essential treatment for diabetes.